1370 - Ocriplasmin for symptomatic vitreomacular adhesion (sVMA) including macular hole

Page last updated: 16 June 2016

Application Detail



Description of Medical Service

Optical coherence tomography (OCT) is part of standard
clinical practice for diagnosing a wide range of macular and retinal diseases. It is proposed that OCT be used as a procedure in patients with sVMA including those associated with full thickness macular hole (FTMH) for the purpose of identifying eligibility for treatment with ocriplasmin (on the Pharmaceutical Benefits Scheme); and for assessment of treatment outcome.

Description of Medical Condition

Vitreomacular interface disorders describe a group of pathologies each with their own distinctive features that distort or blur vision and potentially impair central visual acuity, including vitreomacular adhesion/traction and macular holes.

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation

7 February 2014 – 21 March 2014
Consultation Protocol (PDF 1825 KB)
Consultation Protocol (Word 2427 KB)

Final Protocol (PDF 939 KB)
Final Protocol (Word 1986 KB)

Assessment Report


Public Summary Document

November 2014:
Public Summary Document (PDF 134 KB)
Public Summary Document (Word 111 KB)

March 2016:
Public Summary Document (PDF 63 KB)
Public Summary Document (Word 68 KB)

OCT broader implementation issues - MSAC's advice to the Minister:
OCT broader implementation issues (PDF 66 KB)
OCT broader implementation issues (Word 66 KB)

Meetings for this Application


12 December 2013


8 October 2014


26 November 2014
30 March 2016